Beam Therapeutics (NASDAQ:BEAM) Given New $70.00 Price Target at Wells Fargo & Company
Beam Therapeutics (NASDAQ:BEAM – Free Report) had its price target trimmed by Wells Fargo & Company from $75.00 to $70.00 in a research report sent to investors on Wednesday, MarketBeat Ratings reports. The firm currently has an overweight rating on the stock. BEAM has been the subject of several other reports. Wedbush reiterated an “outperform” […]
Beam Therapeutics (NASDAQ:BEAM – Free Report) had its price target trimmed by Wells Fargo & Company from $75.00 to $70.00 in a research report sent to investors on Wednesday, MarketBeat Ratings reports. The firm currently has an overweight rating on the stock. BEAM has been the subject of several other reports. Wedbush reiterated an “outperform” […]
